Abstract
Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Current Vascular Pharmacology
Title: Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Volume: 4 Issue: 1
Author(s): Atte Meretoja and Turgut Tatlisumak
Affiliation:
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Abstract: Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Export Options
About this article
Cite this article as:
Meretoja Atte and Tatlisumak Turgut, Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203108
DOI https://dx.doi.org/10.2174/157016106775203108 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery Review of the Biological Activity of Maslinic Acid
Current Drug Targets Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Recent Applications of Peanut Phytoalexins
Recent Patents on Food, Nutrition & Agriculture Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Current Pharmaceutical Design Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine Mediterranean Diet and Hypertension; From the Clinical and Epidemiologic Evidences to Prevention
Current Hypertension Reviews How Does HIV Cause Depletion of CD4 Lymphocytes? A Mechanism Involving Virus Signaling Through its Cellular Receptors
Current Molecular Medicine Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology HDL - Cholesterol: The New Target for Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Inflammatory Biomarkers in Atrial Fibrillation
Current Medicinal Chemistry